



15th November 2016

## BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
<b>Indices</b>			
Dow Jones	18868.69	+0.11%	+8.28%
S&P 500	2164.2	-0.01%	+5.88%
Nasdaq	5218.4	-0.36%	+4.21%
Nikkei	17668.15	-0.03%	-7.15%
Stoxx 600	338.23	+0.22%	-7.54%
CAC 40	4508.55	+0.43%	-2.77%
<b>Oil /Gold</b>			
Crude WTI	43.32	-0.21%	+16.45%
Gold (once)	1215.63	-1.05%	+14.43%
<b>Currencies/Rates</b>			
EUR/USD	1.0723	-1.22%	-1.29%
EUR/CHF	1.07075	-0.15%	-1.53%
German 10 years	0.254	+11.88%	-59.93%
French 10 years	0.823	+12.04%	-16.07%

#### Economic releases :

Date	
15th-Nov	08h00 DE - GDP 3Q 10h00 IT - GDP 3Q 10h30 UK - CPI Oct. (1.1% E) 10h30 UK - CPI Core Oct. (1.4% E) 11h00 DE - ZEW Survey Nov. 11h00 DE - ZEW Eco Sentiment Nov.

#### Upcoming BG events :

Date	
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference
18th-Nov	ENGIE (BG Luxembourg roadshow with IR)
24th-Nov	IMERYS (BG London roadshow with IR)
28th-Nov/ 29th-Nov	2nd Paris Consumer Conference
5th-Dec/ 6th-Dec	ATOS (BG Paris Roadshow)
8th-Dec	Reversse roadshow Brewers Netherlands, Belgium

#### Recent reports :

Date	
9th-Nov	VOLTALIA Starting to play with the big boys
8th-Nov	FOCUS INNATE Liri to shine at the upcoming SITC congress
7th-Nov	FOCUS ACCORHOTELS On the right track
3rd-Nov	Casino The fat Lady has not sung yet
20th-Oct	Luxury goods :We bet on a rebound in Greater China in 2017
19th-Oct	IPSEN Cabometyx AND Somatuline to transform Ipsen

List of our Reco & Fair Value : Please click here to download

### INDRA SISTEMAS

NEUTRAL, Fair Value EUR12 (+12%)

*Q3 2016 results below consensus due to "one-offs", 2016 targets reiterated*

Yesterday evening Indra reported Q3 2016 results below consensus due to the loss of a BPO contract in Spain and a "one-off" election deal in Brazil. However, restructuring is advancing according to plan, net debt is stable, and management reiterated 2016 expectations and 2018 targets. We cannot rule out the prospect of a negative share price reaction short term, but the turnaround is confirmed.

### SALVATORE FERRAGAMO NEUTRAL vs. BUY, Fair Value EUR23,8 vs. EUR24,5 (+9%)

*Q3 results below expectations, penalised by wholesale*

Salvatore Ferragamo's Q3 results were below expectations, significantly penalised by wholesale sales with a 4% sales decrease, implying -6% in Q3 alone versus -3.1% in H1. Nevertheless, retail sales recovered in Q3 (+0.5% vs -3.1% in H1) while wholesale sales deteriorated significantly (-19%) during the quarter. We revise down our FY 2016 estimates by 3%. Given poor visibility on the short term, we downgrade our recommendation from Buy to Neutral with a new EUR23.8 FV vs EUR24.5.

#### In brief...

#### ERYTECH, Marketing approval further delayed in Europe. FV revised down

Erytech yesterday announced they it has decided to withdraw the MAA (marketing authorisation application) for GRASPA in Europe

#### UBISOFT, Good first ratings for the new opus of the Watch Dogs franchise

The first reviews of Watch Dogs 2 came out yesterday in the afternoon. The key media outlets gave good ratings for this new opus, with an aggregate score of 85/100 on the PS4

## TMT

## Indra Sistemas

Price EUR10.75

## Q3 2016 results below consensus due to "one-offs", 2016 targets reiterated

Fair Value EUR12 (+12%)

NEUTRAL

Bloomberg	IDR SM
Reuters	IDR.MC
12-month High / Low (EUR)	12.3 / 7.7
Market Cap (EURm)	1,764
Ev (BG Estimates) (EURm)	2,456
Avg. 6m daily volume (000)	693.5
3y EPS CAGR	

Yesterday evening Indra reported Q3 2016 results below consensus due to the loss of a BPO contract in Spain and a "one-off" election deal in Brazil. However, restructuring is advancing according to plan, net debt is stable, and management reiterated 2016 expectations and 2018 targets. We cannot rule out the prospect of a negative share price reaction short term, but the turnaround is confirmed.

## ANALYSIS

• **Q3 2016 results below consensus due to Vodafone.** For Q3 2016, Indra has reported sales down 6.3% (-5.4% lfl) to EUR618.7m, or 7% above our EUR580.7m estimate and only 1% below consensus (EUR624.7m). Non-IFRS operating profit was up 45.7% to EUR34.1m (5.5% of sales, +2ppt) while we expected EUR34.6m or 6% of sales (consensus: EUR37.8m or 6.1% of sales). Net profit was EUR17.4m (vs. a net loss of EUR125.1m in Q3 2015), 19% above our EUR14.6m estimate but 10% below consensus (EUR19.3m). The rise in profitability was the result of higher direct margins on projects, efficiency plans and fewer onerous projects; 1) personnel costs were down only 2.5% in Q3 (vs. -10% in H1) due to a one-time Elections project completed in late October with the Regional Court of Justice in Brazil (c. 3,600 staff) and extra costs linked to the cancellation of a BPO contract with Vodafone in Spain; 2) materials consumed and other opex were down 14.7%; 3) Brazil had an EBIT at breakeven (vs. a loss of EUR33m in Q3 2015) with sales down 4% and opex down 17%.

• **Net debt stable.** Net debt on 30th September 2016 was EUR666.4m (net gearing: 187%) or 3.1x EBITDA, in line with the level as of 30th June. Free cash flow was a negative EUR4.6m (vs. a negative EUR23.2m in Q3 2015). Excluding restructuring cash-outs (EUR12m) and onerous projects (EUR9m), net debt would have reached EUR646m and free cash flow EUR16m. Assuming the same level of non-recourse factoring as in Q3 2015, free cash flow would have been a negative EUR19m. Net working capital fell to EUR198m from EUR232m in December 2015, or to 26 days of sales from 30, o/w +1 day on inventory, -5 days for accounts receivables, and 0 days for accounts payables.

• **Details on Q3 2016 lfl growth. By geography,** Spain (42% of sales) was down 1% with double-digit falls in Telecoms & Media, Government and Transport & Traffic and double-digit growth in Defence & Security (F110 frigate, 8x8 armoured vehicle, NH90 simulator), America (25%) down 16% due to Argentina and Mexico, Europe (19%) up 1%, and AMEA (13%) down 5%. **By vertical,** Transport/Traffic (22%) was down 13% due to delays in some projects, Defence/Security (22%) was up 14%, Energy/Industry (15%) was down 4%, Financial Services (18%) was up 1%, Government/Healthcare (15%) was down 19% due to a lower contribution from the Elections business, and Telecom/Media (8%) was down 14% due to the loss of the Vodafone BPO deal.

• **FY16 outlook reiterated.** Indra reiterates expectations for 2016 on sales (a decline), margins (significant improvement) and free cash flow (significant improvement as well with a positive Q4). Order intake in Q3 2016 was up 9% lfl and the book-to-bill ratio was 0.78x (vs. 0.66x in Q3 2015). On costs, 90% of 1,750 layoffs planned within the efficiency plan have been completed in Spain (Brazil completed in Q4 2015), Indra is in line with the EUR90m in cost savings expected for 2016, and year-to-date restructuring cash-outs (EUR38m) are on track with the EUR45-55m projected for the year. In addition, "one-off" costs (Vodafone, election project in Brazil) will no longer be seen in Q4. Finally, management reiterates its FY18 operating margin target (10-11%).

## VALUATION

- Indra's shares are trading at est. 15.4x 2016 and 9.6x 2017 EV/EBIT multiples.
- Net debt on 30th September 2016 was EUR666.4m (net gearing: 187%).

## NEXT CATALYSTS

FY16 results in February 2017.

[Click here to download](#)

Analyst :  
Gregory Ramirez  
33(0) 1 56 68 75 91  
gramirez@bryangarnier.com

Sector Team :  
Richard-Maxime Beaudoux  
Thomas Coudry  
Dorian Terral



## Luxury &amp; Consumer Goods

## Salvatore Ferragamo

Price EUR21.81

Q3 results below expectations, penalised by wholesale

Fair Value EUR23,8 vs. EUR24,5 (+9%)

NEUTRAL vs. BUY

Bloomberg	SFER IM
Reuters	SFER MI
12-month High / Low (EUR)	23.2 / 17.5
Market Cap (EURm)	3,681
Ev (BG Estimates) (EURm)	3,686
Avg. 6m daily volume (000)	628.3
3y EPS CAGR	5.2%

	1 M	3 M	6 M	31/12/15
Absolute perf.	-4.8%	4.3%	2.4%	0.3%
Pers & H/H Gds	-5.6%	-8.8%	-4.2%	-5.0%
DJ Stoxx 600	-0.5%	-2.3%	1.1%	-7.5%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	1,430	1,420	1,500	1,585
% change		-0.7%	5.6%	5.7%
EBITDA	324	318	340	362
EBIT	264.7	261.0	285.0	307.0
% change		-1.4%	9.2%	7.7%
Net income	172.6	167.0	184.0	201.0
% change		-3.2%	10.2%	9.2%

	2015	2016e	2017e	2018e
Operating margin	18.5	18.4	19.0	19.4
Net margin	12.1	11.8	12.3	12.7
ROE	30.0	26.4	26.2	26.1
ROCE	26.2	22.9	23.1	23.1
Gearing	0.8	0.6	0.4	0.7

(EUR)	2015	2016e	2017e	2018e
EPS	1.02	0.99	1.09	1.19
% change	-	-3.2%	10.2%	9.2%
P/E	21.3x	22.0x	20.0x	18.3x
FCF yield (%)	2.9%	2.3%	2.6%	2.9%
Dividends (EUR)	0.47	0.53	0.60	0.68
Div yield (%)	2.2%	2.4%	2.8%	3.1%
EV/Sales	2.6x	2.6x	2.5x	2.3x
EV/EBITDA	11.4x	11.6x	10.8x	10.2x
EV/EBIT	13.9x	14.1x	12.9x	12.0x

Salvatore Ferragamo's Q3 results were below expectations, significantly penalised by wholesale sales with a 4% sales decrease, implying -6% in Q3 alone versus -3.1% in H1. Nevertheless, retail sales recovered in Q3 (+0.5% vs -3.1% in H1) while wholesale sales deteriorated significantly (-19%) during the quarter. We revise down our FY 2016 estimates by 3%. Given poor visibility on the short term, we downgrade our recommendation from Buy to Neutral with a new EUR23.8 FV vs EUR24.5.

## ANALYSIS

Salvatore Ferragamo's 9m sales reached EUR1.01bn (consensus: EUR1.02bn), down 0.7% and 4% at same forex. This implies a 6% organic revenues decrease in Q3 alone (consensus:-0.5%) versus -3.1% in H1 and -3.4% in Q2. The disappointment was due to wholesale sales (35% of group sales) down 7.3% over 9m and more importantly, down 19% in Q3, strongly penalised by a very cautious shipping approach towards Department Stores, particularly in US, in order to avoid markdowns that *in fine* had a negative impact on brand equity. On the other hand, retail sales had a better performance in Q3 and were almost stable following -3% in H1 and even -6% in Q2. **Actually, on a same store basis, retail sales declined 3% in Q3 after -6% in H1.** This acceleration was driven in particular by **Mainland China** where sales were up 5% in Q3 versus -5% in H1.

By region, we would highlight the slight improvement in **Asia-Pacific** (35% of sales) with a 3.3% decrease following -4.4% in H1 and even -6.4% in Q3. This confirmed that momentum is clearly improving in Greater China (22% of group sales), while the trend remains very well oriented in other Asian countries like Korea and Singapore. In Q3, **Mainland China** (10% of sales) confirmed its turnaround, initiated in Q2 with 7% growth. On the other hand, **Hong Kong** and **Macau** remained clearly under pressure. In **Europe** (26% of sales), sales momentum deteriorated with a 9% decline mainly due to a lack of tourists and also to the wholesale business decrease (-12%), again due to delivery cautionness. The faster decline in **North American** revenues (-7% vs -1.6% in Q3) was due to the clear deterioration in wholesale while retail sales were up.

## Organic sales growth by region

in %	Q1 16	Q2 16	H1 16	Q3 16	9M 16
Europe	-4.2	-2.2	-3.1	-8.6	-4.8
North America	-3.8	-1.6	-2.6	-7.0	-3.9
Japan	0.0	-10.6	-5.2	-16.8	-9.1
Asia-Pacific	-2.0	-6.4	-4.4	-3.3	-4.1
Others	8.4	15.3	12.0	14.6	12.8
<b>Group</b>	<b>-2.3</b>	<b>-3.4</b>	<b>-3.1</b>	<b>-5.9</b>	<b>-4.0</b>

Source : Company Data; Bryan Garnier & Co. ests.

9m EBITDA of EUR216m (consensus: EUR223m) implied a 6% decline in Q3 alone, penalised by i/ lower than expected a sales and ii/ one-off costs linked to management changes, following the departure of Mr. Norsa as CEO. Therefore EBITDA margin lost 130bp in Q3 alone and remained stable over 9m.

**New CEO, Mr. Eraldo Poletto**, is set to focus on i/ store efficiency (improving sales per store which is far below the sector average) instead of store openings, ii/ brand equity and iii/ products, hence new designer appointments (both for the leather goods and shoes activities). Following the poor 9m results, we adjust our FY estimates and expect a 2% organic sales decline (-0.5% previously) and EBITDA margin slight decline (-30bp).

## VALUATION

The stock is trading on a 3% premium versus the luxury sample 2017 EV/EBIT. Given our FV adjustments and low visibility on the short term, we prefer to **downgrade our recommendation from Buy to Neutral with a new FV at EUR23.8 vs EUR24.5.**

## NEXT CATALYSTS

FY 2016 sales to be reported end of January 2017

[Click here to download](#)



Analyst :  
Loïc Morvan  
33(0) 1 70 36 57 24  
lmorvan@bryangarnier.com

Sector Team :  
Nikolaas Faes  
Antoine Parison  
Cédric Rossi  
Virginie Roumage



## Healthcare

**ERYTech**

Price EUR17.47

**Marketing approval further delayed in Europe. FV revised down**

Fair Value EUR30 vs. EUR47 (+72%)

BUY

Bloomberg	ERYP.FP
Reuters	ERYP.PA
12-month High / Low (EUR)	29.0 / 16.1
Market Cap (EURm)	139
Avg. 6m daily volume (000)	15.30

	1 M	3 M	6 M	31/12/15
Absolute perf.	6.1%	-13.1%	-25.3%	-31.8%
Healthcare	-2.7%	-7.9%	-2.8%	-13.3%
DJ Stoxx 600	-0.5%	-2.3%	1.1%	-7.5%

	2014	2015e	2016e	2017e
P/E	NS	NS	NS	NS
Div yield (%)	NM	NM	NM	NM

**ANALYSIS**

- Erytech yesterday announced they it has decided to withdraw the MAA (marketing authorisation application) for GRASPA in Europe. Efficacy and safety-wise, the clinical package has not been called into question. However, the company believes that it would need more time than the procedures allow to address all of the requests from the CHMP (1/ additional data comparability between the old form of asparaginase that was included in the red blood cells in the last Phase III vs the newer one; 2/ development of a new immunogenicity test; 3/ Q&A around the pharmacodynamics). So in very concrete terms, we estimate the marketing approval could be delayed by c.2 years (given that management said it intends to resubmit the MAA by mid-2017).
- Obviously the stock will react quite negatively this morning; and the very next catalyst is quite a hard one to play (see our previous comments for further details). That said, we remain positive on the fundamentals behind GRASPA in ALL and its rationale in AML. And we believe the latter should be seen as a buffer in the very near term (given that it amounts to c.EUR5 per share in our SOP).

**VALUATION**

- We revise down our FV from EUR47 to EUR30 as 1/ we have increased our average WACC from 12.5% to 15.0%, and 2/ delayed our first sales assumption by nearly two years.

**NEXT CATALYSTS**

- Q1 2016: Phase II results for ERY-ASP/GRASPA for the treatment of pancreatic cancer.
- H2 2016: Phase II results for GRASPA in acute myeloid leukaemia.

[Click here to download](#)Mickael Chane Du, [mchanedu@bryangarnier.com](mailto:mchanedu@bryangarnier.com)

TMT

## Ubisoft

Price EUR30.49

Good first ratings for the new opus of the *Watch Dogs* franchise

Fair Value EUR35 (+15%)

BUY

## ANALYSIS

The first reviews of *Watch Dogs 2* came out yesterday in the afternoon (i.e. a day before its release on consoles). The key media outlets gave **good ratings for this new opus, with an aggregate score of 85/100 on the PS4** (journalists have given preference to the PS4 console for their test: based on 36 ratings collected by metacritic). Whereas ratings do not determine sales for a mass market game, they are key for a core-gamer title with important co-op and online parts such as *Watch Dogs 2*. At this point in the cycle, note that a game is considered as an AAA with a score of over 80/100. **The recent good games we have tracked received average ratings of 82-83/100**. As a result, **the 85/100 for *Watch Dogs 2* is very satisfactory and reassuring**.

**This score for *Watch Dogs 2* compares with 79/100 for *Assassin's Creed Syndicate* (80/100 on Xbox One and 78/100 on PS4) and 82/100 for *The Division* (83/100 on PS4 and 81/100 on Xbox One) both released last year, and 79.5/100 for *Watch Dogs 1* launched two years ago (82/100 on PS4 and 77/100 on Xbox One).** Note also that **the direct competitor of *Watch Dogs 2* is *Mafia III* from Take-Two Interactive** (released on 7th October) **which had a very bad score of 68/100** (69/100 on PS4 and 67/100 on Xbox one).

UBI is releasing *Watch Dogs 2* today on PS4 and Xbox One (and on 29th Nov. on PC). **We expect 9m units over FY 2016/17 as we preferred to be cautious given low preorders**. Gamers are in "wait and see" mode, so the quality of the game will be key for a potential positive word of mouth (cf. what we already saw with *Rainbow Six* and *Far Cry 3*). When we look at the pre-tests of *Watch Dogs 2*, **the quality seems to be really good and is now officially translated in its score**. So, we believe **these positive reviews could help the gradual ramp-up of sales** (the sequential weekly sales performances will be interesting to follow) **and lead to a positive surprise vs. the recent lowered sales guidance**. The quality is usually a better indicator than preorders for final sales. The first episode sold at an estimated 10.5m units over FY 2014-15 as it was the first truly next-gen game and also benefited from a release window with almost no competition.

## VALUATION

We maintain our **Buy recommendation** and **FV of EUR35** (only based on fundamentals).

## NEXT CATALYSTS

Q3 sales: February 2017. [Click here to download](#)

Bloomberg	UBI.FP
Reuters	UBIP.PA
12-month High / Low (EUR)	38.3 / 19.0
Market Cap (EUR)	3,461
Avg. 6m daily volume (000)	273.5

	1 M	3 M	6 M	31/12/15
Absolute perf.	-5.0%	-16.9%	1.6%	14.3%
Softw. & Comp.				
SVS	-6.6%	-5.9%	3.8%	-1.5%
DJ Stoxx 600	-0.5%	-2.3%	1.1%	-7.5%
	03/16	03/17e	03/18e	03/19e
P/E	30.0x	27.5x	16.8x	12.2x
Div yield (%)	NM	NM	NM	NM

Richard-Maxime Beaudoux, [rmbeaudoux@bryangarnier.com](mailto:rmbeaudoux@bryangarnier.com)

## BG's Wake Up Call

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 56.1%

NEUTRAL ratings 32.5%

SELL ratings 11.5%

## Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

London	Paris	New York	Munich
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle Prudential et de Résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany <b>+49 89 2422 62 11</b>



## BRYAN, GARNIER & Co

### Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

### Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

### Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

### Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

### Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

### Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....